Stock Scorer

SynAct Pharma AB (SYNACT.ST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in SEK. Every figure as a table ›

Revenue Annual

0 FY21: 0 FY22: 0 FY23: 0 FY24: 0 FY25: 0 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 FY21: 0 FY22: 0 FY23: 0 FY24: 0 FY25: 0 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-240M -160M -80M 0 80M 160M 240M FY21: -76.7M FY22: -105.7M FY23: -224.5M FY24: -90M FY25: -116.5M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-240M -160M -80M 0 80M 160M 240M FY21: -69.3M FY22: -99.2M FY23: -215.8M FY24: -82.4M FY25: -110.8M FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-120M -80M -40M 0 40M 80M 120M FY21: -65M FY22: -117.6M FY23: -100.2M FY24: -89.2M FY25: -97.3M FY21 FY22 FY23 FY24 FY25

EPS Annual

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 FY21: -2.68 FY22: -3.60 FY23: -6.64 FY24: -2.08 FY25: -2.17 FY21 FY22 FY23 FY24 FY25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for SYNACT.ST: Cost of Revenue, Free Cash Flow, Shares Outstanding. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.